Last update 29 Aug 2025
Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.

Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.

Subsidiary Company|1995|Hebei Sheng, China|
www.ieye.com.cn

Overview

Tags

Nervous System Diseases
Endocrinology and Metabolic Disease
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
MAO-B(Monoamine oxidase B)1

Related

1
Drugs associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
Rasagiline mesylate
Target
MAO-B
Mechanism
MAO-B inhibitors
Active Org.
Viatris Ltd. (New Zealand) [+9]
Originator Org.
Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd. [+1]
Active Indication
Parkinson Disease [+1]
Inactive Indication
Dementia due to Alzheimer's disease (disorder) [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date21 Feb 2005
6
Clinical Trials associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
CTR20242374
/ CompletedPhase 1
盐酸毛果芸香碱滴眼液人体药代动力学试验
[Translation] Pharmacokinetics of pilocarpine hydrochloride eye drops in humans
CTR20241981
/ CompletedPhase 3
盐酸毛果芸香碱滴眼液用于成人老视患者的有效性和安全性的随机、多中心、双盲、安慰剂对照临床试验
[Translation] A randomized, multicenter, double-blind, placebo-controlled clinical trial on the efficacy and safety of pilocarpine hydrochloride eye drops in adult patients with presbyopia
CTR20222723
/ CompletedPhase 1
评估低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次给药的安全性、耐受性和药代动力学特征的I期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single/multiple administrations of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects
100 Clinical Results associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Rasagiline mesylate
 ( MAO-B )		Primary Parkinson's disease
More
Phase 1
Atropine Sulfate
 ( mAChRs )		Myopia
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free